AI-generated summary
The authors report a randomized controlled trial in 192 volunteers undergoing coronary artery bypass graft surgery, comparing photobiomodulation (intravenous and transdermal laser) with standard treatment alone. Of those enrolled, 170 completed the study. The authors report lower LDH and CPK levels, fewer postoperative complications, and lower pain scores in the laser group, and describe PBM as promising and safe.
- Participants
- 170
- Who or what was studied
- Volunteers electively undergoing coronary artery bypass graft surgery, randomized into a photobiomodulation group or a standard-treatment control group; 170 of 192 completed the study.
- Wavelengths
- 980, 405 nm
- Limits stated in the abstract
- The abstract does not describe blinding, long-term follow-up, or whether the reported safety conclusion was specifically tested beyond the postoperative period.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 980 nm, 405 nm
- Energy density (fluence)
- 6 J/cm2
- Power
- 200 mW, 1.5 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Laser, Control group, Visual analogue scale, Trial registration, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.